View Older Stories View More Recent Stories

Nov 17, 2025 06:00AM Zymeworks reports positive phase 3 trial results for cancer drug Ziihera
May 15, 2025 08:03AM ZJK Industrial (ZJK) Secures Patent from the China National Intellectual Property Administration for High-Precision Image Recognition-based SMT Carrier Tape Inspection System
Mar 31, 2025 12:00PM Form X-17A-5 FIRST ANALYSIS SECURITIE For: Dec 31
Oct 9, 2024 08:35AM Gilead Sciences (GILD) to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek
Sep 27, 2024 11:06AM Bristol-Myers Squibb (BMY) Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
Jun 6, 2024 09:00AM Sware Raises $6M to Accelerate Life Sciences Innovation by Automating FDA-Mandated Software Validation
Jun 6, 2024 08:01AM Madrigal Pharma (MDGL) Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra
Jun 6, 2024 08:00AM Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Jun 3, 2024 04:00PM Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
Jun 3, 2024 05:51AM Intellia Therapeutics (NTLA) Reports Positive Long-Term Data from Phase 1 Study of NTLA-2002
Jun 2, 2024 08:00AM Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
May 7, 2024 08:01AM Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Apr 30, 2024 08:00AM Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Apr 28, 2024 04:30PM CYTALUX Real-World Experience Presented at the American Association for Thoracic Surgery 104th Annual Meeting
Apr 17, 2024 01:20AM Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
Apr 17, 2024 01:15AM Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Apr 17, 2024 01:15AM Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Apr 8, 2024 12:05PM Exact Sciences (EXAS) to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR
Apr 8, 2024 12:05PM Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
Apr 4, 2024 08:00AM Candel Therapeutics (CADL) Reports Positive Interim Data from Randomized Phase 2 Trial of CAN-2409
Apr 4, 2024 08:00AM Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Mar 28, 2024 04:42PM Form X-17A-5 FIRST ANALYSIS SECURITIE For: Dec 31
Feb 23, 2024 11:12AM Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging
Jan 22, 2024 05:00PM Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Jan 10, 2024 02:00PM Lykos Therapeutics (Formerly MAPS PBC) Announces Publication Examining the Effects of MDMA-Assisted Therapy on Emotional Coping Skills and Self-Experience in PTSD
Oct 25, 2023 04:32AM Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
Oct 24, 2023 04:47AM Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
Oct 22, 2023 03:00PM Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Oct 22, 2023 02:59PM Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Oct 3, 2023 08:10AM AMRA Used in Tirzepatide Analyses Evaluating the Effect on Muscle Composition via MRI
Sep 20, 2023 08:58AM Gemspring Capital Acquires ClearCompany
Aug 25, 2023 06:24AM Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA
Aug 25, 2023 06:15AM Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squam
Aug 23, 2023 09:00AM Verizon Business 2023 Payment Security Report: Insights to reduce payment security complexity
Aug 11, 2023 02:59PM Form D First Analysis Fund XIV-
Aug 8, 2023 11:00AM Stamus Networks Raises $6M Series A to Expose and Eradicate Serious Threats and Unauthorized Activity in Enterprise Networks
Aug 8, 2023 09:20AM BrightRock Gold Corp. Receives High-Resolution Satellite Imagery Results for its Midnight Owl Lithium Property near Wickenburg, Arizona
Aug 3, 2023 02:49PM Form D First Analysis Fund XIV
Jul 27, 2023 07:00AM Alabama Hands-Free Law Reduces Distracted Driving 2.4%
Jul 26, 2023 04:01PM Form D First Analysis Fund XIV,
Jul 19, 2023 12:00PM ThoughtSpot Completes $200M Acquisition of Mode Analytics
Jun 26, 2023 12:00PM ThoughtSpot Acquires Mode Analytics for $200M to Empower Data Teams to Redefine Business Intelligence with Trusted Generative AI
Jun 22, 2023 06:00AM Madrigal Pharma (MDGL) Presents Phase 3 MAESTRO-NASH Data
Jun 22, 2023 03:30AM Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
Jun 20, 2023 08:00AM Avinger Announces Presentations by Key Opinion Leaders at LINC 2023
Jun 12, 2023 08:30AM RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
Jun 12, 2023 08:00AM Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in
Jun 12, 2023 05:24AM Intellia Therapeutics (NTLA) Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002
Jun 11, 2023 08:30AM Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Jun 6, 2023 08:30AM COVID-19 vaccination: No serious side effects in young children
View More Recent Stories View Older Stories